Related Experiment Video

Updated: Dec 29, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

981

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Daixi Ren1,2,3, Yuze Hua1,2,3, Boyao Yu1,2,3

  • 1NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.

Molecular Cancer
|February 1, 2020
PubMed

Insights

Immune checkpoint blockade targeting PD-1/PD-L1 shows promise but faces resistance. This review explores predictive biomarkers, resistance mechanisms, and combination therapies for improved precision medicine in cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Precision Medicine

Background:

  • Immune checkpoint inhibitors targeting PD-1/PD-L1 offer therapeutic benefits for various cancers.
  • Treatment resistance remains a significant challenge in PD-1/PD-L1 blockade therapy.

Purpose of the Study:

  • To review predictive biomarkers for PD-1/PD-L1 blockade efficacy.
  • To explore mechanisms of immunotherapy resistance.
  • To propose combination therapeutic strategies for enhanced cancer treatment.

Main Methods:

  • Analysis of PD-L1 expression levels.
  • Assessment of tumor mutation burden.
  • Evaluation of immune cell infiltration and function.
  • Review of mechanisms of T cell dysfunction and exhaustion.

Main Results:

  • PD-L1 expression, mutation burden, and immune cell status are key predictors of treatment response.
  • Tumor cell PD-L1 expression, T cell dysfunction, and exhaustion contribute to resistance.
  • Combination therapies can overcome resistance mechanisms.

Conclusions:

  • Personalized treatment plans incorporating predictive biomarkers and combination strategies are crucial for effective precision medicine.
  • Understanding resistance mechanisms guides the development of novel therapeutic approaches.
  • This review provides a framework for optimizing PD-1/PD-L1 blockade therapy.
Keywords:
Cancer immunotherapyImmune cellsImmune checkpoint blockadePD-1/PD-L1Precision medicine

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.3K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K